Sign up for our free daily newsletter
Get the latest news and some fun stuff
in your inbox every day
Get the latest news and some fun stuff
in your inbox every day
Medical device company Stryker demonstrated a robust performance in the fourth quarter, with reported net sales increasing by 11.8% to $5.8 billion thanks to rising demand for elective surgeries. Stryker has been a Vestact-recommended stock since January 2014, exactly a decade ago.
Last week Stryker, our preferred stock in the medical devices industry, issued market-beating results with revenue of $4.9 billion, up 9.6% year-on-year, and earnings per share of $2.46. Even with that handy beat on revenue and profits, the share price dropped 0.8% on Friday because hip and knee replacement revenue was lower than expected.
Last week our medical technology holding Stryker reported solid numbers. Sales increased by 11.2% to $5 billion which resulted in an adjusted earnings per share increase of 12.9% to $2.54. They expect to make just over $10 a share for the full year. That puts the stock on a forward multiple of 28 times earnings. This is pretty standard for a quality operation showing consistent growth in a thriving industry.
A week ago Stryker reported strong first-quarter earnings and provided an upbeat outlook for the fiscal year. The medical device company's sales came in at $4.80 billion, up 11.8% year-over-year (or 14% in constant currency), surpassing the consensus estimate of $4.56 billion.
One of our portfolio shares traded at an all-time high yesterday - medical device maker Stryker. We added them to our recommended portfolio in late January 2014. The chart below shows what they have done since then.
After a tough 2022, this earnings season is a bit more tense than usual. Vestact-recommended medical device company Stryker reported numbers after the market's close last night, thankfully beating both top and bottom line expectations. As mentioned above, the stock rose smartly in after-hours trading.
On Monday night, Stryker, the medical device business, released their numbers for the third quarter of the year. My son had his tonsils taken out the other day. Whilst in the theatre I was pleased to see a Stryker surgical monitor (like the picture below), which was linked to Stryker equipment used to perform the surgery. All went well.
Stryker is always innovating in the medical devices arena. They recently launched the Gamma4 Hip Fracture Nailing System which according to the company does the following.
Medical device-maker Stryker has been a Vestact-recommended stock since January 2014. In that time they've made good progress, growing sales from around $10 billion a year to $18 billion. Profits have risen steadily too, and so has the share price.
We have a client who works in the medical devices industry and he sent me an update from Stryker, who are struggling with chip shortages. Stryker has to bid for these chips through a broker, and that's crimping margins. They expect this to continue throughout the year.
Medical technology company Stryker reported mixed fourth-quarter results last week. Not for the first time, Covid delayed many elective surgical procedures. The company reported revenues of $4.70 billion and profits of $662 million for the quarter, up 10.3% and 16.5% year-on-year, respectively.
On Thursday Stryker announced that they are buying Vocera Communications for $3 billion. Here is a high-level description of the business: "Vocera caters to nearly 1 900 hospitals, allowing healthcare workers to communicate and collaborate with co-workers and engage with patients and their families". Looking at their website, they seem to be a hospital management system making it easy for staff members to interact with each other and have easy access to patient information.
Stryker was hit hard by Covid because elective surgeries were halted and hospitals' priorities changed drastically. As the world slowly normalises, the recovery has been lumpy. People needing hip and knee replacements have booked appointments in droves but theatre staff are in short supply as Covid variants keep popping up.
Medical device-maker Stryker reported second-quarter numbers last week. The results were fine, and the stock moved to a new all-time high above $270 per share.
Picture this. You are a Vestact client and you wake up on a Saturday morning, make yourself a coffee and check your emails. Your weekly mini-statement pops up and you scroll through it briefly. Looking good, nice to see Stryker above $260 a share again. You delete the email and go for a run.